Regeneron Pharmaceuticals (REGN) reported positive Phase 3 results for cemdisiran in Generalized Myasthenia Gravis, with the NIMBLE trial meeting primary and key secondary endpoints at 24 weeks.
Cemdisiran-treated patients showed significant improvements in MG-ADL and QMG scores versus placebo, with placebo-adjusted gains of 2.3 points and 2.8 points, respectively.
Clinical benefits appeared within two weeks and were sustained through the study period. Notably, 76.6% of patients achieved =3-point MG-ADL improvement compared to 44.1% on placebo.
The investigational siRNA therapy targets complement factor C5 and is administered once every 12 weeks, offering a potentially more convenient treatment option.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.